IFNAR Inhibitor

IFNAR Inhibitors (59):

Cat. No.	Product Name	Effect	Purity

HY-100941

CCCP	Inhibitor	99.83%
CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.

HY-117287

Deucravacitinib	Inhibitor	99.93%
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis.

HY-P10710A

BMP-4 acetate	Inhibitor	99.30%
BMP-4 acetate is a penetrating heparin-binding peptide with anti-inflammatory and anti-chondrogenic functions. BMP-4 acetate regulates the iNOS-IFN-IL6 signaling pathway to inhibit the expression of inflammatory proteins such as iNOS, COX2, IFN, and IL6, effectively suppressing inflammation and alleviating various arthritis symptoms in murine chondrocytes and macrophages.

HY-174802

XL-3158	Inhibitor	99.55%
XL-3158 is a selective and cross-species Cyclic GMP-AMP synthase (cGAS) inhibitor (IC₅₀: 11.1 μM for human cGAS, 2.19 μM for mouse cGAS). XL-3158 simultaneously occupy allosteric and orthosteric sites, stabilizing the activation loop in a closed, inactive conformation and thereby attenuating the cGAS-DNA interactions. XL-3158 inhibits cGAS by targeting phase separation. XL-3158 efficiently penetrates cells by inhibiting aggregate formation, effectively reducing the local concentration of cGAS within cells. XL-3158 has no obvious cytotoxicity within the effective concentration range and is suitable for subsequent cell function experiments. XL-3158 overcomes species selectivity barriers and serves as a drug candidate for cGAS-dependent inflammatory diseases.

HY-P99168

Anifrolumab	Inhibitor	99.48%
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.

HY-147124

RIG012	Inhibitor	≥99.0%
RIG012 is a potent RIG-I inhibitor with an IC₅₀ of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.

HY-150095

YE6144	Inhibitor
YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation.

HY-P99191

Emapalumab	Inhibitor	98.86%
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (K_d= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH).

HY-12836A

IFN alpha-IFNAR-IN-1 hydrochloride	Inhibitor	99.76%
IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC₅₀=2-8 μM).

HY-P99137

Anti-Mouse IFNAR1 Antibody (MAR1-5A3)	Inhibitor	99.00%
Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing antibody of IFNAR1. Anti-Mouse IFNAR1 Antibody (MAR1-5A3) reacts with IFNAR1 and inhibits IFNAR1 signaling in vitro and in vivo. Mouse IgG1 kappa, Isotype Control (HY-P99977) is the isotype control of Anti-Mouse IFNAR1 Antibody (MAR1-5A3).

HY-171006

IRF1-IN-1	Inhibitor	99.72%
IRF1-IN-1 (Compound I-2) is an IRF1 inhibitor. IRF1-IN-1 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-1 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1). IRF1-IN-1 has a protective effect on ionizing radiation-induced inflammatory skin injury.

HY-P99136

Anti-Mouse IFN gamma Antibody (H22)	Inhibitor
Anti-Mouse IFN gamma Antibody (H22) is an anti-mouse IFN gamma IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse IFN gamma Antibody (H22) abrogates specific binding of ^I25II-rIFN-γ to macrophages. Anti-Mouse IFN gamma Antibody (H22) inhibits macrophage-activating factor (MAF) (ID₅₀ = 56 ng). Anti-Mouse IFN gamma Antibody (H22) inhibits IFN-gamma dependent antiviral activity (ID₅₀ = 2 ng). Anti-Mouse IFN gamma Antibody (H22) neutralizes IFNγ in mice. Anti-Mouse IFN gamma Antibody (H22) can be used for the researches of inflammation and infection, such as arthritis.

HY-107390

AX-024	Inhibitor	99.73%
AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC₅₀ ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.

HY-151385

VVD-118313	Inhibitor	99.75%
VVD-118313 (compound 5a) is a potent, selective JAK1 inhibitor. VVD-118313 targets an isoform-restricted allosteric cysteine to block JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancer. VVD-118313 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P1934A

Cyclo(L-Phe-L-Pro)	Inhibitor	99.91%
Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC₅₀ of 24 µM in the DPPH assay.

HY-171007

IRF1-IN-2	Inhibitor	99.83%
IRF1-IN-2 (Compound I-19) is an IRF1 inhibitor. IRF1-IN-2 decreases the recruitment of IRF1 to the promoter of CASP1. IRF1-IN-2 inhibits cell death signaling pathway (i.e., cleavage of Caspase 1, GSDMD, IL-1 and PARP1; inhibits the Pho of TKB1, upregulates GPX4 and downregulates FACL4). IRF1-IN-2 has a protective effect on ionizing radiation-induced inflammatory skin injury.

HY-P990036

Dazukibart	Inhibitor	99.76%
Dazukibart (PF-06823859) is a potent, selective humanized IgG1 neutralizing monoclonal antibody that targets interferon β (IFNβ). Dazukibart can be used in the study of moderate to severe dermatomyositis.

HY-76938

Actarit	Inhibitor	99.58%
Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II (CAII) inhibitor with an IC₅₀ of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII)-induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis.

HY-N1363

Royal Jelly acid	Inhibitor	99.42%
Royal Jelly Acid ((E)-Queen Bee Acid) is a major fatty acid found in royal jelly with oral bioavailability, exhibiting anti-inflammatory, anticancer, antimalarial, antiprotozoal, and neuroregulatory activities. Royal Jelly Acid can be used for research in various fields, including cancer, infections, immune inflammation, and neurological diseases.

HY-119347

Cirsilineol	Inhibitor	≥98.0%
Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4⁺ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.

Name
Email *

	Sorry, but the email address you supplied was invalid.